Severity staging of chronic obstructive pulmonary disease: Differences in pre- and post-bronchodilator spirometry

Yonsei Medical Journal

Volumn 50, Issue 5, 2009, Pages 672-676

  Lin, Sheng Hsiang ^a   Kuo, Ping Hung ^b   Kuo, Sow Hsong ^b   Yang, Pan Chyr ^b  

^a Taipei County Hospital   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bronchodilator test; Chronic obstructive pulmonary disease; Severity staging

Indexed keywords

FENOTEROL;

AGED; ARTICLE; BRONCHODILATATION; BRONCHOSPIROGRAPHY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INHALATION TEST; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE;

BRONCHODILATOR AGENTS; FENOTEROL; FORCED EXPIRATORY VOLUME; HUMANS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPIROMETRY;

EID: 70449724677     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2009.50.5.672     Document Type: Article

References (26)

1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Workshop report: National Institutes of Health, National Heart, Lung and Blood Institute, Update 2008.
2. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012 (Pubitemid 38269277)
3. O'Donnell RA, Peebles C, Ward JA, Daraker A, Angco G, Broberg P, et al. Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD. Thorax 2004;59:837-842 (Pubitemid 39389622)
4. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Stolk J, Sont JK, Jansen DF, et al. Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:499-504. (Pubitemid 39209130)
5. Doi M, Nakano K, Hiramoto T, Kohno N. Significance of pulmonary artery pressure in emphysema patients with mild-to-moderate hypoxemia. Respir Med 2003;97:915-920 (Pubitemid 36944121)
6. Antonelli-Incalzi R, Imperiale C, Bellia V, Catalano F, Scichilone N, Pistelli R, et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003;22:444-449
7. Morris A, Sciurba FC, Lebedeva IP, Githaiga A, Elliott WM, Hogg JC, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004;170:408-413 (Pubitemid 39214615)
8. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653 (Pubitemid 38787999)
9. Donohue JF. Therapeutic responses in asthma and COPD. Bronchodilators. Chest 2004;126:125S-37S.
10. Sterk PJ. Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J 2004;23:497-498
11. Standardization of spirometry - 1987 update. Statement of the American Thoracic Society. Am Rev Respir Dis 1987;136:1285-1298
12. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society. Am Rev Respir Dis 1991;144:1202-1218
13. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398-1420
14. Yang SC. [Re-evaluation of the ventilatory function in a normal Chinese: comparison with the results of a survey conducted 15 years ago.] J Formos Med Assoc 1993;92 Suppl 3:S152-9.
15. Perng DW, Huang HY, Chen HM, Lee YC, Perng RP. Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment. Chest 2004;126:375-381
16. Reid DW, Soltani A, Johns DP, Bish R, Williams TJ, Burns GP, et al. Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease. Intern Med J 2003;33:572-577 (Pubitemid 38121802)
17. Quadrelli SA, Roncoroni AJ, Montiel GC. Evaluation of bronchodilator response in patients with airway obstruction. Respir Med 1999;93:630-636 (Pubitemid 29476252)
18. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-664 (Pubitemid 36976273)
19. Sourk RL, Nugent KM. Bronchodilator testing: confidence intervals derived from placebo inhalations. Am Rev Respir Dis 1983;128:153-157
20. Huchon G, Hofbauer P, Cannizzaro G, Iacono P, Wald F. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO. Eur Respir J 2000;15:663-669 (Pubitemid 30196292)
21. Hodder R, Pavia D, Dewberry H, Alexander K, Iacono P, Ponitz H, et al. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler. Respir Med 2005;99:1087-1095 (Pubitemid 41102645)
22. Roncoroni AJ, Goldman E, Puy RJ, Mancino M. Bronchoconstriction induced by repeated forced vital capacity manoeuvres. Acta Allergol 1975;30:375-389
23. Hubbard R, Tattersfield A, Smith C, West J, Smeeth L, Fletcher A. Use of inhaled corticosteroids and the risk of fracture. Chest 2006;130:1082-1088 (Pubitemid 44583738)
24. Lee TA, Weiss KB. Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:855-859 (Pubitemid 38402463)
25. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A. Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;159:1267-1271 (Pubitemid 29202565)
26. Chanez P, Vignola AM, O'Shaugnessy T, Enander I, Li D, Jeffery PK, et al. Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 1997;155:1529-1534 (Pubitemid 27216654)